Guggenheim Capital’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Guggenheim Capital’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-10,945	Closed	-$1.08M	–	1936
2024 Q3	$1.08M	Sell	10,945 -9,713	-47%	-$954K	0.01%	1060
2024 Q2	$1.92M	Hold	20,658	–	–	0.01%	827
2024 Q1	$1.96M	Hold	20,658	–	–	0.01%	887
2023 Q4	$1.84M	Hold	20,658	–	–	0.01%	875
2023 Q3	$1.51M	Sell	20,658 -227	-1%	-$18.1K	0.01%	921
2023 Q2	$1.74M	Sell	20,885 -106	-0.5%	-$8.87K	0.01%	916
2023 Q1	$1.6M	Buy	20,991 +4,099	+24%	+$340K	0.01%	946
2022 Q4	$1.4M	Buy	16,892 +8,527	+102%	+$690K	0.01%	1005
2022 Q3	$664K	Buy	+8,365	New	+$705K	0.01%	1355

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

Guggenheim Capital's XBI Position: Q4 2024 in Review

Guggenheim Capital sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2024, closing a stake of 10,945 shares — an estimated $1.08M sold.

Guggenheim Capital first reported a position in XBI in Q3 2022 and held it in 9 quarters. The position peaked at $1.96M in Q1 2024. 738 funds tracked by Wall St. Rank hold XBI as of Q4 2024.

Guggenheim Capital reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2024 after selling out during the quarter.
Guggenheim Capital sold 10,945 State Street SPDR S&P Biotech ETF shares in Q4 2024, an estimated $1.08M.
Guggenheim Capital first reported a position in State Street SPDR S&P Biotech ETF in Q3 2022 and held it in 9 quarters.
Guggenheim Capital's State Street SPDR S&P Biotech ETF position peaked at $1.96M in Q1 2024.
738 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2024.

Based on Guggenheim Capital's 13F filing for Q4 2024, filed 13 Feb 2025.